Emtricitabine

Emtricitabine
(em tra cye’ tah ben)
Emtriva
PREGNANCY CATEGORY B
Drug Classes
Anti-HIV drug
Antiviral
Nucleoside reverse transcriptase inhibitor
Therapeutic Actions
HIV-1 reverse transcriptase inhibitor; competes with a natural substrate and is incorporated into the viral DNA, leading to chain termination.
Indications
  • In combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults and children
Available Forms
Capsules—200 mg; oral solution—10 mg/mL
Dosages
Adults
200 mg daily PO, with or without food or 240 mg (24 mL) oral solution/day PO.
Pediatric patients 3 mo–17 yr
6 mg/kg PO once daily to a maximum 240 mg (24 mL) oral solution; children weighing more than 33 kg and able to swallow a capsule may take one 200-mg capsule/day PO.
Pediatric patients up to 3 mo
3 mg/kg oral solution PO once daily
Patients with renal impairment
For dialysis patients, 200 mg PO every 96 hr. For renally impaired patients, use these dosages:
CrCl (mL/min) Capsule Dosage (mg) Oral Solution Dosage (mg)
50 or more 200 daily 240 every 24 hr
30–49 200 every 48 hr 120 every 24 hr
15–29 200 every 72 hr 80 every 24 hr
Less than 15 200 every 96 hr 60 every 24 hr

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 20, 2016 | Posted by in NURSING | Comments Off on Emtricitabine

Full access? Get Clinical Tree

Get Clinical Tree app for offline access